S
Savara Pharmaceuticals
An inhaled antibiotic for mrsa infection in cystic fibrosis
About Savara Pharmaceuticals
Savara Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases. The company primarily serves patients with unmet medical needs, particularly those suffering from conditions such as autoimmune pulmonary alveolar proteinosis (aPAP) and non-cystic fibrosis bronchiectasis (NCFB). Operating in the orphan lung disease market, Savara's business model revolves around conducting advanced clinical trials to bring novel treatments to market.
Savara's revenue model is based on the successful development and commercialization of its drug candidates. The company is currently engaged in multiple clinical studies, including a pivotal Phase 3 study called AVAIL, which evaluates AeroVanc for treating MRSA in cystic fibrosis patients. Another key project is the Phase 3 clinical study of Molgradex for aPAP, with plans to discuss a confirmatory study for NCFB with the U.S. Food and Drug Administration (FDA).
By focusing on rare diseases, Savara aims to provide better treatment options for patients who have limited alternatives. The company's strategic approach includes leveraging its expertise in respiratory conditions to develop targeted therapies that can significantly improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Austin, United States
- Listing
- IPO 2017
- Employees
- 126
- Open positions
- 19
- Dealroom signal
- 88.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jun 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jan 2026 | $0 | — | Hercules Capital | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2025 | $130M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Savara Pharmaceuticals is 5.6K monthly website visits, up 24.4% over the last three months. Savara Pharmaceuticals's team grew 250% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Savara Pharmaceuticals in the Austin ecosystem
The Savara Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cystic Fibrosis Foundation
Series A6 investors entered at this stage
Keiretsu Forum Mid Atlantic
Green Park & Golf Ventures
Keiretsu Forum Northwest
Keiretsu Forum
Rady Venture Fund
Tech Coast Angels
Series B and later14 investors entered at this stage
- HPHaas Portman
Keiretsu Capital
Carthona Capital
Standard Treasury
Silicon Valley Bank
Wellington Management
TCGX
Bain Capital Life Sciences
Farallon Capital Management- NMNantahala Capital Management
- FMFirst Light Asset Management
Frazier Life Sciences
Hercules Capital
RTW Investments
Other known investors10 additional known investors
Mast Therapeutics
University of Kansas- 3V37 Ventures
Austin Technology Incubator
Central Texas Angel Network
James Synge
Keiretsu Forum Australiasia- PCPuget Sound Venture Club
Small Business Innovation Research
Wild Basin Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Savara Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Savara Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










